BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 20182796)

  • 1. Weight gain is associated with increased risk of hot flashes in breast cancer survivors on aromatase inhibitors.
    Su HI; Sammel MD; Springer E; Freeman EW; DeMichele A; Mao JJ
    Breast Cancer Res Treat; 2010 Nov; 124(1):205-11. PubMed ID: 20182796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of postdiagnosis weight change on hot flash status among early-stage breast cancer survivors.
    Caan BJ; Emond JA; Su HI; Patterson RE; Flatt SW; Gold EB; Newman VA; Rock CL; Thomson CA; Pierce JP
    J Clin Oncol; 2012 May; 30(13):1492-7. PubMed ID: 22430275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and risk factors for insomnia among breast cancer patients on aromatase inhibitors.
    Desai K; Mao JJ; Su I; Demichele A; Li Q; Xie SX; Gehrman PR
    Support Care Cancer; 2013 Jan; 21(1):43-51. PubMed ID: 22584732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of subjective and objective hot flash measures over time among breast cancer survivors initiating aromatase inhibitor therapy.
    Otte JL; Flockhart D; Hayes D; Storniolo AM; Stearns V; Schneider B; Henry NL; Azzouz F; Nguyen A; Lemler S; Hayden J; Jeter S; Wright L; Carpenter JS
    Menopause; 2009; 16(4):653-9. PubMed ID: 19455068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Side effects of aromatase inhibitors versus tamoxifen: the patients' perspective.
    Garreau JR; Delamelena T; Walts D; Karamlou K; Johnson N
    Am J Surg; 2006 Oct; 192(4):496-8. PubMed ID: 16978958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen.
    Kimmick GG; Lovato J; McQuellon R; Robinson E; Muss HB
    Breast J; 2006; 12(2):114-22. PubMed ID: 16509835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tamoxifen-induced hot flashes.
    Loprinzi CL; Zahasky KM; Sloan JA; Novotny PJ; Quella SK
    Clin Breast Cancer; 2000 Apr; 1(1):52-6. PubMed ID: 11899390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Morning chronotype is a protective factor against chemotherapy-induced hot flashes in premenopausal women with breast cancer.
    Son KL; Jung D; Lee KM; Hwang H; Lee J; Kim TY; Im SA; Lee KH; Spiegel D; Hahm BJ
    Support Care Cancer; 2020 Mar; 28(3):1351-1358. PubMed ID: 31264189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of menopausal symptoms in postmenopausal breast cancer patients treated with aromatase inhibitors.
    Hong D; Bi L; Zhou J; Tong Y; Zhao Q; Chen J; Lu X
    Oncotarget; 2017 Jun; 8(25):40558-40567. PubMed ID: 28489562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Menopausal-type symptoms among breast cancer patients on aromatase inhibitor therapy.
    Gallicchio L; MacDonald R; Wood B; Rushovich E; Helzlsouer KJ
    Climacteric; 2012 Aug; 15(4):339-49. PubMed ID: 22191462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific adverse events are associated with response to exemestane therapy in postmenopausal breast cancer patients: Results from the TEAMIIA study (BOOG2006-04).
    Fontein DB; Charehbili A; Nortier JW; Putter H; Kranenbarg EM; Kroep JR; Linn SC; van de Velde CJ
    Eur J Surg Oncol; 2017 Apr; 43(4):619-624. PubMed ID: 28017458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study.
    Pandya KJ; Raubertas RF; Flynn PJ; Hynes HE; Rosenbluth RJ; Kirshner JJ; Pierce HI; Dragalin V; Morrow GR
    Ann Intern Med; 2000 May; 132(10):788-93. PubMed ID: 10819701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trial of a hypnosis intervention for treatment of hot flashes among breast cancer survivors.
    Elkins G; Marcus J; Stearns V; Perfect M; Rajab MH; Ruud C; Palamara L; Keith T
    J Clin Oncol; 2008 Nov; 26(31):5022-6. PubMed ID: 18809612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hot flashes in breast cancer survivors: Frequency, severity and impact.
    Chang HY; Jotwani AC; Lai YH; Jensen MP; Syrjala KL; Fann JR; Gralow J
    Breast; 2016 Jun; 27():116-21. PubMed ID: 27065357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors.
    Mao JJ; Stricker C; Bruner D; Xie S; Bowman MA; Farrar JT; Greene BT; DeMichele A
    Cancer; 2009 Aug; 115(16):3631-9. PubMed ID: 19517460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The addition of hormone therapy to tamoxifen does not prevent hot flashes in women at high risk for developing breast cancer.
    Osborne CR; Duncan A; Sedlacek S; Paul D; Holmes F; Vukelja S; Kasper M; Wilks S; Schneider A; McGee R; Meyer WG; O'Shaughnessy JA
    Breast Cancer Res Treat; 2009 Aug; 116(3):521-7. PubMed ID: 19139988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hot flashes and related outcomes in breast cancer survivors and matched comparison women.
    Carpenter JS; Johnson D; Wagner L; Andrykowski M
    Oncol Nurs Forum; 2002 Apr; 29(3):E16-25. PubMed ID: 11979290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant aromatase inhibitor therapy and early markers for cardiovascular disease in breast cancer survivors.
    van Ommen-Nijhof A; Jacobse JN; Steggink LC; Lefrandt JD; Gietema JA; van Leeuwen FE; Schaapveld M; Sonke GS
    Breast Cancer Res Treat; 2022 Dec; 196(3):591-602. PubMed ID: 36181605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, placebo-controlled trial of testosterone for treatment of postmenopausal women with aromatase inhibitor-induced arthralgias: Alliance study A221102.
    Cathcart-Rake E; Novotny P; Leon-Ferre R; Le-Rademacher J; Storrick EM; Adjei AA; Terstriep S; Glaser R; Giuliano A; Mitchell WR; Page S; Austin C; Deming RL; Ferreira MA; Lafky JM; Birrell SN; Loprinzi CL
    Support Care Cancer; 2021 Jan; 29(1):387-396. PubMed ID: 32372176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and genetic risk factors for aromatase inhibitor-associated arthralgia in breast cancer survivors.
    Romero SAD; Su HI; Satagopan J; Li QS; Seluzicki CM; Dries A; DeMichele AM; Mao JJ
    Breast; 2020 Feb; 49():48-54. PubMed ID: 31678641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.